The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment

Exclusion Criteria

• •Treatment on other interferon preparations, glatiramer acetate, in last 30 days or 6 months on Natalizumab, mitoxantrone, cyclosporine or other immunomodulators as determined by the PI.
• •Treatment with any other investigational treatments within the past year or treatment with any investigational treatments for multiple sclerosis within the last year.
• •Any progressive form of MS.
• •Known Hypersensitivity to interferon beta 1a.
• •Inability to administer subcutaneous injections
• •Inability to undergo laboratory evaluation.
• •Seropositivity for HIV (by medical history)
• •Diabetes Mellitus Tyle I or II (by medical history)
• •Hepatitis B or C (by medical history)
• •Uncontrolled psychiatric disorder.
• •Any unstable illness that the investigator's opinion precludes participation in this study.
• •Inability to maintain compliance with study protocol.
• •Implanted devices or metal which would contraindicate MRI.
• •Clinically significant abnormalities in CBC or CMP
• •MMSE \<25